The effect of Venetoclax in the treatment of leukemia

Venetoclax/Venetoclax (Venetoclax) is a targeted therapy drug mainly used to treat chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin lymphoma (NHL). Its unique mechanism of action is to promote the apoptosis of infected white blood cells by inhibiting BCL-2 (BCL-2) protein, thus controlling the growth and spread of abnormal cells. Many patients experience positive disease responses and improved survival with venetoclax/venetoclax.

1. Clinical Experimental Data

1.1 The efficacy of chronic lymphocytic leukemia (CLL)

A number of clinical trials have shown that Venetoclax/Venetoclax has shown significant effects in the treatment of CLL. In a pivotal clinical trial, such as the MURANO trial, venetoclax was combined with the anti-CD20 antibody obinutuzumab (Obinutuzumab) >) Compared with the traditional treatment plan of fludarabine (fludarabine), triamterene (cyclophosphamide) and the anti-CD20 antibody solfitinib, the combined treatment plan is more effective in treating-naïve Demonstrated significant disease response rate and survival advantage in patients with CLL. After treatment, the overall survival of patients is longer and disease recurrence is less likely to occur.

1.2 Therapeutic effect of non-Hodgkin lymphoma (NHL)

For some specific typesNHL,Venetoclax/Venetoclax also demonstrated positive therapeutic effects. In some clinical studies, venetoclax as a monotherapy or in combination with other drugs has achieved significant disease control in patients with refractory/relapsed disease.

2. Mechanism and Pharmacology

Venetoclax/Venetoclax’s mechanism of action is mainly through selective inhibition ofBCL-2 protein, which is a protein that inhibits apoptosis. Overexpression of BCL-2 is closely associated with the development of malignant diseases such as leukemia and lymphoma. Venetoclax/Venetoclax works by promoting apoptosis of leukemia and lymphoma cells, thereby effectively inhibiting the proliferation of abnormal cells.

3. Medication plan

Patients should receive a detailed evaluation by their physician before usingvenetoclax/venetoclax. The dosage and frequency of use will be based on the patient's condition and your doctor's recommendations. Typically, the initial dose may be gradually increased to ensure that the patient tolerates the drug. During the treatment process, the doctor will adjust the treatment plan based on the patient's response and condition.

4. Side effects

Venetoclax/Venetoclax treatment is also associated with some possible side effects, such as nausea, vomiting, diarrhea and other digestive system discomforts, as well as anemia, neutropenia and other hematopoietic system reactions. However, these side effects are usually controllable and manageable, and doctors will monitor closely and take appropriate measures during treatment.

5. Warnings and Precautions

When using venetoclax/venetoclax, patients need to pay attention to potential drug interactions, especially other anti-cancer drugs, antibiotics, etc. Patients should follow their doctor's advice and promptly report any discomfort or unusual symptoms.

6. Contraindications

Venetoclax/Venetoclaxmay be contraindicated in patients allergic to Venetoclax/Venetoclax or its components. Pregnant women, especially those in the first trimester, should also avoid use.

7. Drug interactions

Special attention needs to be paid to possible drug interactions when using venetoclax/venetoclax. Patients should inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, and supplements, before use.

8. Drug use for special groups

Pregnant and lactating women, as well as patients with impaired liver or kidney function, need to be cautious when using venetoclax/venetoclax and use it under the guidance of a doctor.

Venetoclax/VenetoclaxAs a targeted therapy drug, through its unique mechanism of action, it has demonstrated significant effects in the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clinical trial data show that Venetoclax/Venetoclax can not only effectively control the disease, but also brings a significant survival advantage. However, patients need to closely follow their doctor's recommendations during use, receive regular monitoring, and be aware of possible side effects and drug interactions. Under the guidance of doctors, Venetoclax/Venetoclax provides an important treatment option for leukemia patients and has made a positive contribution to improving the patient's quality of life and prolonging their survival.

Venekra/Venetoclax has been launched in China and has been included in medical insurance. Patients can purchase it domestically. Specifications: 100mg*14tablets and the price is around 5,000yuan. Please consult the local hospital pharmacy for specific prices. There are original drugs and generic drugs abroad. The Turkish version of Venetoclax/Venetoclaxoriginal drug on the market overseas, specification: 100mg*112 tablets, costs about 10,000 per box. Foreign generic drugs are relatively cheaper. For example, the generic drugs sold in Laos and Bangladesh are priced at about more than 4,000 yuan for 100mg*120 tablets. The ingredients of original drugs and generic drugs are basically the same.